Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]

Inclusion Criteria: * age of at least 18 years * adult subject living in the same household as a related COVID-19 patient (index person) Exclusion Criteria: * index person has COVID-19 symptoms for more than 5 days at enrolment * known past COVID-19 or current infection confirmed by positive SARS-CoV-2 PCR test at enrolment * symptoms at enrolment indicating COVID-19: increased body temperature OR acute respiratory symptoms of any severity OR newly occuring loss of taste or smell OR ague OR sumulatneously occuring headache and body ache * known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of Driponin®) * known chronic obstructive pulmonary disease * known acute or chronic hepatitis B or C or other clinically recognizable or known liver dysfunction * known HIV infection or AIDS * known symptomatic allergic rhinitis * current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ASS (including prophylactic use), metamizol) * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs * known or clinically suspected disturbance of the blood-brain-barrier (e.g., ABCB-1 (=MDR1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (P-gp) * known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate * pregnancy or lactation * women of child-bearing potential planning to become pregnant or not using effective mehods of contraception * any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation * previous or planned (during next 14 days) vaccination with any COVID-19 vaccine * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with Ivermectin * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating COVID-19 in alignemnt with RKI * apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days) * known alcohol or drug abuse * participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days * previous participation in this same clinical trial